U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C56H87NO16
Molecular Weight 1030.2892
Optical Activity UNSPECIFIED
Defined Stereocenters 15 / 15
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEMSIROLIMUS

SMILES

C[C@]1([H])/C(/[H])=C(\[H])/C(/[H])=C(\[H])/C(/[H])=C(\C)/[C@]([H])(C[C@]2([H])CC[C@@]([H])(C)[C@@](C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O[C@@]([H])(CC(=O)[C@]([H])(C)/C(/[H])=C(\C)/[C@]([H])([C@]([H])(C(=O)[C@]([H])(C)C1)OC)O)[C@]([H])(C)C[C@]4([H])CC[C@]([H])([C@@]([H])(C4)OC)OC(=O)C(C)(CO)CO)(O)O2)OC

InChI

InChIKey=CBPNZQVSJQDFBE-FUXHJELOSA-N
InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1

HIDE SMILES / InChI

Molecular Formula C56H87NO16
Molecular Weight 1030.2892
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 15 / 15
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022088s000_PRNTLBL.pdf

Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel. Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.76000000000000001 µM [IC50]
Target ID: CHEMBL614067
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Torisel

Approved Use

Treatment of advanced renal cell carcinoma (RCC)

Launch Date

1180396800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
585 ng/mL
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TEMSIROLIMUS blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1627 ng × h/mL
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TEMSIROLIMUS blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.3 h
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TEMSIROLIMUS blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
11%
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TEMSIROLIMUS blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg/m2 1 times / week multiple, intravenous
Dose: 150 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / week
Sources:
unhealthy, 11 years (range: 4-21 years)
Health Status: unhealthy
Age Group: 11 years (range: 4-21 years)
Sex: M+F
Sources:
DLT: Anorexia...
Dose limiting toxicities:
Anorexia (grade 3, 1 patient)
Sources:
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
DLT: Stomatitis, Asthenia...
Other AEs: Mucositis, Mucositis...
Dose limiting toxicities:
Stomatitis (grade 3, 1 patient)
Asthenia (grade 3, 1 patient)
Other AEs:
Mucositis (grade 1-2, 7 patients)
Mucositis (grade 3-4, 1 patient)
Nausea (grade 1-2, 5 patients)
Thrombocytopenia (grade 1-2, 1 patient)
Diarrhea (grade 1-2, 1 patient)
Vomiting (grade 1-2, 3 patients)
Hypercholesterolemia (grade 3-4, 2 patients)
Hypertriglyceridemia (grade 3-4, 1 patient)
Peripheral edema (grade 1-2, 2 patients)
Weight loss (grade 1-2, 2 patients)
Taste perversion (grade 1-2, 2 patients)
Sources:
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Other AEs: Asthenia, Asthenia...
Other AEs:
Asthenia (all grades, 51%)
Asthenia (grade 3-4, 11%)
Edema (all grades, 35%)
Edema face (all grades, 35%)
Peripheral edema (all grades, 35%)
Edema (grade 3-4, 3%)
Edema face (grade 3-4, 3%)
Peripheral edema (grade 3-4, 3%)
Pain (all grades, 28%)
Pain (grade 3-4, 5%)
Pyrexia (all grades, 24%)
Pyrexia (grade 3-4, 1%)
Weight loss (all grades, 19%)
Weight loss (grade 3-4, 1%)
Headache (all grades, 15%)
Headache (grade 3-4, 1%)
Chest pain (all grades, 16%)
Chest pain (grade 3-4, 1%)
Chills (all grades, 8%)
Chills (grade 3-4, 1%)
Aphthous stomatitis (all grades, 41%)
Glossitis (all grades, 41%)
Mouth ulceration (all grades, 41%)
Mucositis (all grades, 41%)
Stomatitis (all grades, 41%)
Aphthous stomatitis (grade 3-4, 3%)
Glossitis (grade 3-4, 3%)
Mouth ulceration (grade 3-4, 3%)
Mucositis (grade 3-4, 3%)
Stomatitis (grade 3-4, 3%)
Anorexia (all grades, 32%)
Anorexia (grade 3-4, 3%)
Nausea (all grades, 37%)
Nausea (grade 3-4, 2%)
Diarrhea (all grades, 27%)
Diarrhea (grade 3-4, 1%)
Abdominal pain (all grades, 21%)
Abdominal pain (grade 3-4, 4%)
Constipation (all grades, 20%)
Vomiting (all grades, 19%)
Vomiting (grade 3-4, 2%)
Infection NOS (all grades, 20%)
Abscess (all grades, 20%)
Bronchitis (all grades, 20%)
Cellulitis (all grades, 20%)
Herpes simplex (all grades, 20%)
Herpes zoster (all grades, 20%)
Infection NOS (grade 3-4, 3%)
Abscess (grade 3-4, 3%)
Bronchitis (grade 3-4, 3%)
Cellulitis (grade 3-4, 3%)
Herpes simplex (grade 3-4, 3%)
Herpes zoster (grade 3-4, 3%)
Cystitis (all grades, 15%)
Dysuria (all grades, 15%)
Hematuria (all grades, 15%)
Urinary frequency (all grades, 15%)
Urinary tract infection (all grades, 15%)
Cystitis (grade 3-4, 1%)
Dysuria (grade 3-4, 1%)
Hematuria (grade 3-4, 1%)
Urinary frequency (grade 3-4, 1%)
Urinary tract infection (grade 3-4, 1%)
Pharyngitis (all grades, 12%)
Rhinitis (all grades, 10%)
Back pain (all grades, 20%)
Back pain (grade 3-4, 3%)
Arthralgia (all grades, 18%)
Arthralgia (grade 3-4, 1%)
Myalgia (all grades, 8%)
Myalgia (grade 3-4, 1%)
Dyspnea (all grades, 28%)
Dyspnea (grade 3-4, 9%)
Cough (all grades, 26%)
Cough (grade 3-4, 1%)
Epistaxis (all grades, 12%)
Eczema (all grades, 47%)
Exfoliative dermatitis (all grades, 47%)
Maculopapular rash (all grades, 47%)
Pruritic rash (all grades, 47%)
Pustular rash (all grades, 47%)
Rash NOS (all grades, 47%)
Vesiculobullous rash (all grades, 47%)
Epistaxis (grade 3-4, 5%)
Eczema (grade 3-4, 5%)
Exfoliative dermatitis (grade 3-4, 5%)
Maculopapular rash (grade 3-4, 5%)
Pruritic rash (grade 3-4, 5%)
Pustular rash (grade 3-4, 5%)
Rash NOS (grade 3-4, 5%)
Vesiculobullous rash (grade 3-4, 5%)
Pruritus (all grades, 19%)
Pruritus (grade 3-4, 1%)
Nail disorder (all grades, 14%)
Dry skin (all grades, 11%)
Dry skin (grade 3-4, 1%)
Acne (all grades, 10%)
Taste loss (all grades, 20%)
Taste perversion (all grades, 20%)
Insomnia (all grades, 12%)
Insomnia (grade 3-4, 1%)
Depression (all grades, 4%)
Conjunctivitis (7%)
Hypersensitivity reaction (9%)
Pneumonia (8%)
Upper respiratory tract infection (7%)
Healing impaired (1%)
Hypertension (7%)
Venous thromboembolism (2%)
Thrombophlebitis (1%)
Hemoglobin decreased (all grades, 94%)
Hemoglobin decreased (grade 3-4, 20%)
Lymphocyte count decreased (all grades, 53%)
Lymphocyte count decreased (grade 3-4, 16%)
Neutrophil count decreased (all grades, 19%)
Neutrophil count decreased (grade 3-4, 5%)
Platelets decreased (all grades, 40%)
Platelets decreased (grade 3-4, 1%)
Leukocyte count decreased (all grades, 32%)
Leukocyte count decreased (grade 3-4, 1%)
Alkaline phosphatase increased (all grades, 68%)
Alkaline phosphatase increased (grade 3-4, 3%)
AST increased (all grades, 38%)
AST increased (grade 3-4, 2%)
Creatinine increased (all grades, 57%)
Creatinine increased (grade 3-4, 3%)
Glucose increased (all grades, 89%)
Glucose increased (grade 3-4, 16%)
Blood phosphorus decreased (all grades, 49%)
Blood phosphorus decreased (grade 3-4, 18%)
Bilirubin total increased (all grades, 8%)
Bilirubin total increased (grade 3-4, 1%)
Cholesterol total increased (all grades, 87%)
Cholesterol total increased (grade 3-4, 2%)
Triglyceride increased (all grades, 83%)
Triglyceride increased (grade 3-4, 44%)
Potassium decreased (all grades, 21%)
Potassium decreased (grade 3-4, 5%)
Sources:
10 mg/m2 3 times / week multiple, intravenous
Dose: 10 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
DLT: Hypertension, Mucositis...
Dose limiting toxicities:
Hypertension (grade 3, 1 patient)
Mucositis (grade 3, 1 patient)
Gamma-glutamyltransferase increased (grade 3, 1 patient)
Hypertriglyceridaemia (grade 4, 1 patient)
Sources:
7.5 mg/m2 2 times / week multiple, intravenous
Dose: 7.5 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 2 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
DLT: Hypertriglyceridemia, Gamma-glutamyltransferase increased...
Dose limiting toxicities:
Hypertriglyceridemia (grade 4, 2 patients)
Gamma-glutamyltransferase increased (1 patient)
Alkaline phosphatase increased (1 patient)
Anorexia (grade 2, 1 patient)
Sources:
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
DLT: Sepsis, Mucositis...
Dose limiting toxicities:
Sepsis (grade 5, 1 patient)
Mucositis (grade 5, 1 patient)
Acidosis (grade 5, 1 patient)
Reversible posterior leukoencephalopathy syndrome (1 patient)
Perianal ulcer (grade 2, 1 patient)
Gamma-glutamyltransferase increased (1 patient)
Sources:
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy
Disc. AE: Interstitial lung disease, Asthenia...
AEs leading to
discontinuation/dose reduction:
Interstitial lung disease (grade 5)
Asthenia (3 patients)
Creatinine increased (3 patients)
Anemia (2 patients)
Abdominal pain (2 patients)
Peripheral edema (2 patients)
Cerebrovascular accident (grade 5, 1 patient)
Dyspnea (1 patient)
Lung infiltration (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anorexia grade 3, 1 patient
DLT
150 mg/m2 1 times / week multiple, intravenous
Dose: 150 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / week
Sources:
unhealthy, 11 years (range: 4-21 years)
Health Status: unhealthy
Age Group: 11 years (range: 4-21 years)
Sex: M+F
Sources:
Diarrhea grade 1-2, 1 patient
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Thrombocytopenia grade 1-2, 1 patient
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Peripheral edema grade 1-2, 2 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Taste perversion grade 1-2, 2 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Weight loss grade 1-2, 2 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Vomiting grade 1-2, 3 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Nausea grade 1-2, 5 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Mucositis grade 1-2, 7 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Asthenia grade 3, 1 patient
DLT
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Stomatitis grade 3, 1 patient
DLT
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Hypertriglyceridemia grade 3-4, 1 patient
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Mucositis grade 3-4, 1 patient
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Hypercholesterolemia grade 3-4, 2 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
Health Status: unhealthy
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Sources:
Healing impaired 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Thrombophlebitis 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Venous thromboembolism 2%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Conjunctivitis 7%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Hypertension 7%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Upper respiratory tract infection 7%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pneumonia 8%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Hypersensitivity reaction 9%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Acne all grades, 10%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Rhinitis all grades, 10%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Dry skin all grades, 11%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Epistaxis all grades, 12%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Insomnia all grades, 12%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pharyngitis all grades, 12%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Nail disorder all grades, 14%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Cystitis all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Dysuria all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Headache all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Hematuria all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Urinary frequency all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Urinary tract infection all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Chest pain all grades, 16%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Arthralgia all grades, 18%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Neutrophil count decreased all grades, 19%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pruritus all grades, 19%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Vomiting all grades, 19%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Weight loss all grades, 19%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Abscess all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Back pain all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Bronchitis all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Cellulitis all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Constipation all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Herpes simplex all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Herpes zoster all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Infection NOS all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Taste loss all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Taste perversion all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Abdominal pain all grades, 21%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Potassium decreased all grades, 21%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pyrexia all grades, 24%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Cough all grades, 26%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Diarrhea all grades, 27%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Dyspnea all grades, 28%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pain all grades, 28%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Anorexia all grades, 32%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Leukocyte count decreased all grades, 32%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Edema face all grades, 35%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Edema all grades, 35%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Peripheral edema all grades, 35%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Nausea all grades, 37%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
AST increased all grades, 38%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Depression all grades, 4%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Platelets decreased all grades, 40%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Aphthous stomatitis all grades, 41%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Glossitis all grades, 41%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Mouth ulceration all grades, 41%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Mucositis all grades, 41%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Stomatitis all grades, 41%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Eczema all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Exfoliative dermatitis all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Maculopapular rash all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pruritic rash all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pustular rash all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Rash NOS all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Vesiculobullous rash all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Blood phosphorus decreased all grades, 49%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Asthenia all grades, 51%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Lymphocyte count decreased all grades, 53%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Creatinine increased all grades, 57%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Alkaline phosphatase increased all grades, 68%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Bilirubin total increased all grades, 8%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Chills all grades, 8%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Myalgia all grades, 8%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Triglyceride increased all grades, 83%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Cholesterol total increased all grades, 87%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Glucose increased all grades, 89%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Hemoglobin decreased all grades, 94%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Arthralgia grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Bilirubin total increased grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Chest pain grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Chills grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Cough grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Cystitis grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Diarrhea grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Dry skin grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Dysuria grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Headache grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Hematuria grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Insomnia grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Leukocyte count decreased grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Myalgia grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Platelets decreased grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pruritus grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pyrexia grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Urinary frequency grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Urinary tract infection grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Weight loss grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Asthenia grade 3-4, 11%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Glucose increased grade 3-4, 16%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Lymphocyte count decreased grade 3-4, 16%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Blood phosphorus decreased grade 3-4, 18%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
AST increased grade 3-4, 2%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Cholesterol total increased grade 3-4, 2%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Nausea grade 3-4, 2%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Vomiting grade 3-4, 2%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Hemoglobin decreased grade 3-4, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Abscess grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Alkaline phosphatase increased grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Anorexia grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Aphthous stomatitis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Back pain grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Bronchitis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Cellulitis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Creatinine increased grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Edema face grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Edema grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Glossitis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Herpes simplex grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Herpes zoster grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Infection NOS grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Mouth ulceration grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Mucositis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Peripheral edema grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Stomatitis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Abdominal pain grade 3-4, 4%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Triglyceride increased grade 3-4, 44%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Eczema grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Epistaxis grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Exfoliative dermatitis grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Maculopapular rash grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Neutrophil count decreased grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pain grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Potassium decreased grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pruritic rash grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Pustular rash grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Rash NOS grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Vesiculobullous rash grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Dyspnea grade 3-4, 9%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
Health Status: unhealthy
Age Group: 59 years (range 23-86)
Sex: M+F
Sources:
Gamma-glutamyltransferase increased grade 3, 1 patient
DLT
10 mg/m2 3 times / week multiple, intravenous
Dose: 10 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Hypertension grade 3, 1 patient
DLT
10 mg/m2 3 times / week multiple, intravenous
Dose: 10 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Mucositis grade 3, 1 patient
DLT
10 mg/m2 3 times / week multiple, intravenous
Dose: 10 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Hypertriglyceridaemia grade 4, 1 patient
DLT
10 mg/m2 3 times / week multiple, intravenous
Dose: 10 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Alkaline phosphatase increased 1 patient
DLT
7.5 mg/m2 2 times / week multiple, intravenous
Dose: 7.5 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 2 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Gamma-glutamyltransferase increased 1 patient
DLT
7.5 mg/m2 2 times / week multiple, intravenous
Dose: 7.5 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 2 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Anorexia grade 2, 1 patient
DLT
7.5 mg/m2 2 times / week multiple, intravenous
Dose: 7.5 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 2 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Hypertriglyceridemia grade 4, 2 patients
DLT
7.5 mg/m2 2 times / week multiple, intravenous
Dose: 7.5 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 2 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Gamma-glutamyltransferase increased 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Reversible posterior leukoencephalopathy syndrome 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Perianal ulcer grade 2, 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Acidosis grade 5, 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Mucositis grade 5, 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Sepsis grade 5, 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
Health Status: unhealthy
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Sources:
Dyspnea 1 patient
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy
Lung infiltration 1 patient
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy
Abdominal pain 2 patients
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy
Anemia 2 patients
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy
Peripheral edema 2 patients
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy
Asthenia 3 patients
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy
Creatinine increased 3 patients
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy
Cerebrovascular accident grade 5, 1 patient
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy
Interstitial lung disease grade 5
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 27 uM]
no
no
no
no
no
no
yes [IC50 14 uM]
yes [IC50 2.2 uM]
no (co-administration study)
Comment: To investigate the inhibition potential of temsirolimus, a drug-drug interaction study with desipramine (a CYP2D6 substrate) was completed. The statistical analysis concludes that the 90% CI for the LSGM ratios of Cmax, AUCt and AUC of desipramine were within the range of 80-125%.
Page: 7
yes [IC50 5.5 uM]
yes
yes
no (co-administration study)
Comment: desipramine concentrations were not effected by co-administration with temsirolimus in-vivo, therefore no inhibition of CYP3A4 of expected.
Page: 7
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Drug-drug interaction studies indicate an 56% reduction in sirolimus exposure (AUC), and no effect on temsirolimus exposure when administered with rifampin. Coadministration of IV temsirolimus with ketoconazole did not effect the exposure of temsirolimus but increased the exposure (AUC) of sirolimus by 3.1-fold.
Page: 7
no
no
no
no
yes
yes
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
2015 Jul
Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.
2015 Jun
Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.
2017 Feb
Patents

Sample Use Guides

Renal Cell Carcinoma
Route of Administration: Intravenous
Temsirolimus (10uM) inhibited the growth of Human Renal Cell Carcinoma Caki-1 growth approx. by 60%
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:11:21 UTC 2021
Edited
by admin
on Sat Jun 26 15:11:21 UTC 2021
Record UNII
624KN6GM2T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TEMSIROLIMUS
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
TEMSIROLIMUS [VANDF]
Common Name English
RAPAMYCIN 42-(2,2-BIS(HYDROXYMETHYL)PROPIONATE)
Common Name English
TORISEL
Brand Name English
TEMSIROLIMUS [JAN]
Common Name English
TEMSIROLIMUS [EMA EPAR]
Common Name English
TEMSIROLIMUS [ORANGE BOOK]
Common Name English
TEMSIROLIMUS [USAN]
Common Name English
TEMSIROLIMUS [WHO-DD]
Common Name English
TEMSIROLIMUS [INN]
Common Name English
RAPAMYCIN, 42-(3-HYDROXY-2-(HYDROXYMETHYL)-2-METHYLPROPANOATE)
Common Name English
CCI-779
Code English
TEMSIROLIMUS [MI]
Common Name English
TEMSIROLIMUS [MART.]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175076
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
EMA ASSESSMENT REPORTS TORISEL (AUTHORIZED: LYMPHOMA, MANTLE-CELL)
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
EMA ASSESSMENT REPORTS TORISEL (AUTHORIZED: CARCINOMA, RENAL CELL)
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
NDF-RT N0000175605
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
NCI_THESAURUS C2201
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
FDA ORPHAN DRUG 196404
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
LIVERTOX 933
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
WHO-ATC L01XE09
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
WHO-VATC QL01XE09
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
EU-Orphan Drug EU/3/06/365
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
Code System Code Type Description
EVMPD
SUB21308
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
IUPHAR
5892
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
HSDB
7931
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
DRUG BANK
DB06287
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
DRUG CENTRAL
4161
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
LACTMED
Temsirolimus
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
INN
8212
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
MERCK INDEX
M10555
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY Merck Index
FDA UNII
624KN6GM2T
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
MESH
C401859
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
PUBCHEM
6918289
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
WIKIPEDIA
Temsirolimus
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201182
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
CAS
162635-04-3
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
EPA CompTox
162635-04-3
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
NCI_THESAURUS
C1844
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
RXCUI
657797
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY RxNorm
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> INHIBITOR
IC50
BINDER->LIGAND
The percentage of [14C]temsirolimus bound to proteins at concentrations of 100 ng/mL when calculated for undiluted human plasma in erythrocyte suspensions was 87.1%.
BINDING
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TARGET -> INHIBITOR
BINDER->LIGAND
The percentage of [14C]temsirolimus bound to proteins at concentrations of 10 ng/mL when calculated for undiluted human plasma in erythrocyte suspensions was 85.0%
BINDING
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

SINGLE DOSE